{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:41:17Z","timestamp":1793385677905,"version":"4.5.0"},"reference-count":43,"publisher":"Rockefeller University Press","issue":"11","license":[{"start":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T00:00:00Z","timestamp":1595289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01AI138398-S1"],"award-info":[{"award-number":["P01AI138398-S1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["2U19AI111825"],"award-info":[{"award-number":["2U19AI111825"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI091707-10S1"],"award-info":[{"award-number":["R01AI091707-10S1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI078788"],"award-info":[{"award-number":["R01AI078788"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R37AI64003"],"award-info":[{"award-number":["R37AI64003"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006369","name":"George Mason University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006369","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European ATAC Consortium","award":["EC101003650"],"award-info":[{"award-number":["EC101003650"]}]},{"DOI":"10.13039\/100001229","name":"G. Harold and Leila Y. Mathers Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001229","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Robert S. Wennett"},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1 TR001866"],"award-info":[{"award-number":["UL1 TR001866"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shapiro-Silverberg Fund for the Advancement of Translational Research"},{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rupress.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,11,2]]},"abstract":"<jats:p>The emergence of SARS-CoV-2 and the ensuing explosive epidemic of COVID-19 disease has generated a need for assays to rapidly and conveniently measure the antiviral activity of SARS-CoV-2\u2013specific antibodies. Here, we describe a collection of approaches based on SARS-CoV-2 spike-pseudotyped, single-cycle, replication-defective human immunodeficiency virus type-1 (HIV-1), and vesicular stomatitis virus (VSV), as well as a replication-competent VSV\/SARS-CoV-2 chimeric virus. While each surrogate virus exhibited subtle differences in the sensitivity with which neutralizing activity was detected, the neutralizing activity of both convalescent plasma and human monoclonal antibodies measured using each virus correlated quantitatively with neutralizing activity measured using an authentic SARS-CoV-2 neutralization assay. The assays described herein are adaptable to high throughput and are useful tools in the evaluation of serologic immunity conferred by vaccination or prior SARS-CoV-2 infection, as well as the potency of convalescent plasma or human monoclonal antibodies.<\/jats:p>","DOI":"10.1084\/jem.20201181","type":"journal-article","created":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T02:21:57Z","timestamp":1594174917000},"update-policy":"https:\/\/doi.org\/10.1084\/jem.crossmarkpolicy","source":"Crossref","is-referenced-by-count":590,"title":["Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses"],"prefix":"10.1084","volume":"217","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7731-6685","authenticated-orcid":true,"given":"Fabian","family":"Schmidt","sequence":"first","affiliation":[{"name":"Laboratory of Retrovirology, The Rockefeller University, New York, NY 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9249-1745","authenticated-orcid":true,"given":"Yiska","family":"Weisblum","sequence":"additional","affiliation":[{"name":"Laboratory of Retrovirology, The Rockefeller University, New York, NY 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0132-5101","authenticated-orcid":true,"given":"Frauke","family":"Muecksch","sequence":"additional","affiliation":[{"name":"Laboratory of Retrovirology, The Rockefeller University, New York, NY 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0554-0244","authenticated-orcid":true,"given":"Hans-Heinrich","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9907-4346","authenticated-orcid":true,"given":"Eleftherios","family":"Michailidis","sequence":"additional","affiliation":[{"name":"Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2492-3961","authenticated-orcid":true,"given":"Julio C.C.","family":"Lorenzi","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2957-1811","authenticated-orcid":true,"given":"Pilar","family":"Mendoza","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8090-3503","authenticated-orcid":true,"given":"Magdalena","family":"Rutkowska","sequence":"additional","affiliation":[{"name":"Laboratory of Retrovirology, The Rockefeller University, New York, NY 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4438-5590","authenticated-orcid":true,"given":"Eva","family":"Bednarski","sequence":"additional","affiliation":[{"name":"Laboratory of Retrovirology, The Rockefeller University, New York, NY 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7295-8128","authenticated-orcid":true,"given":"Christian","family":"Gaebler","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3924-6449","authenticated-orcid":true,"given":"Marianna","family":"Agudelo","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6354-6148","authenticated-orcid":true,"given":"Alice","family":"Cho","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2095-2151","authenticated-orcid":true,"given":"Zijun","family":"Wang","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5976-9717","authenticated-orcid":true,"given":"Anna","family":"Gazumyan","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8156-2512","authenticated-orcid":true,"given":"Melissa","family":"Cipolla","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1727-8693","authenticated-orcid":true,"given":"Marina","family":"Caskey","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7379-3484","authenticated-orcid":true,"given":"Davide F.","family":"Robbiani","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 3"},{"name":"5Institute for Research in Biomedicine, Universit\u00e0 della Svizzera italiana, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0592-8564","authenticated-orcid":true,"given":"Michel C.","family":"Nussenzweig","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 3"},{"name":"Howard Hughes Medical Institute, The Rockefeller University, New York, NY 4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3087-8079","authenticated-orcid":true,"given":"Charles M.","family":"Rice","sequence":"additional","affiliation":[{"name":"Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7889-0766","authenticated-orcid":true,"given":"Theodora","family":"Hatziioannou","sequence":"additional","affiliation":[{"name":"Laboratory of Retrovirology, The Rockefeller University, New York, NY 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2368-3719","authenticated-orcid":true,"given":"Paul D.","family":"Bieniasz","sequence":"additional","affiliation":[{"name":"Laboratory of Retrovirology, The Rockefeller University, New York, NY 1"},{"name":"Howard Hughes Medical Institute, The Rockefeller University, New York, NY 4"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"291","published-online":{"date-parts":[[2020,7,21]]},"reference":[{"key":"2023072622185405900_bib1","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1128\/JVI.59.2.284-291.1986","article-title":"Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone","volume":"59","author":"Adachi","year":"1986","journal-title":"J. Virol"},{"key":"2023072622185405900_bib2","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.3201\/eid2206.160010","article-title":"Antibody Response and Disease Severity in Healthcare Worker MERS Survivors","volume":"22","author":"Alshukairi","year":"2016","journal-title":"Emerg. Infect.                        Dis"},{"key":"2023072622185405900_bib3","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1038\/sj.gt.3301574","article-title":"In vivo gene transfer to the mouse eye using an HIV-based lentiviral vector; efficient long-term transduction of corneal endothelium and retinal pigment epithelium","volume":"8","author":"Bainbridge","year":"2001","journal-title":"Gene Ther"},{"key":"2023072622185405900_bib4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.06.025","article-title":"Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies","author":"Barnes","year":"2020","journal-title":"Cell"},{"key":"2023072622185405900_bib5","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1172\/JCI138745","article-title":"Deployment of convalescent plasma for the prevention and treatment of COVID-19","volume":"130","author":"Bloch","year":"2020","journal-title":"J. Clin.                        Invest"},{"key":"2023072622185405900_bib6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1093\/intimm\/dxx025","article-title":"Diversification of IgG effector functions","volume":"29","author":"Bournazos","year":"2017","journal-title":"Int. Immunol"},{"key":"2023072622185405900_bib7","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc5902","article-title":"Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability","author":"Brouwer","year":"2020","journal-title":"Science"},{"key":"2023072622185405900_bib8","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1017\/S0950268800048019","article-title":"The time course of the immune response to experimental coronavirus infection of man","volume":"105","author":"Callow","year":"1990","journal-title":"Epidemiol. Infect"},{"key":"2023072622185405900_bib9","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1056\/NEJMc070348","article-title":"Disappearance of antibodies to SARS-associated coronavirus after recovery","volume":"357","author":"Cao","year":"2007","journal-title":"N. Engl.                        J. Med"},{"key":"2023072622185405900_bib10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cell.2020.05.025","article-title":"Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients\u2019 B cells","volume":"182","author":"Cao","year":"2020","journal-title":"Cell"},{"key":"2023072622185405900_bib11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40475-020-00201-6","article-title":"The SARS-CoV-2 Vaccine Pipeline: an Overview","author":"Chen","year":"2020","journal-title":"Curr. Trop. Med.                        Rep."},{"key":"2023072622185405900_bib12","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41423-020-0426-7","article-title":"Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor","volume":"17","author":"Chen","year":"2020","journal-title":"Cell. Mol.                        Immunol."},{"key":"2023072622185405900_bib13","doi-asserted-by":"crossref","unstructured":"Chi,X.,R.Yan,J.Zhang,G.Zhang,Y.Zhang,M.Hao,Z.Zhang,P.Fan,Y.Dong,Y.Yang, .2020. A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability.bioRxiv. https:\/\/doi.org\/10.1101\/2020.05.08.083964 (Preprint posted May 8, 2020)","DOI":"10.1101\/2020.05.08.083964"},{"key":"2023072622185405900_bib14","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.3201\/eid2307.170310","article-title":"MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015","volume":"23","author":"Choe","year":"2017","journal-title":"Emerg. Infect.                        Dis"},{"key":"2023072622185405900_bib15","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1006\/viro.1995.1016","article-title":"Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes","volume":"206","author":"Connor","year":"1995","journal-title":"Virology"},{"key":"2023072622185405900_bib16","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3390\/v12050513","article-title":"Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays","volume":"12","author":"Crawford","year":"2020","journal-title":"Viruses"},{"key":"2023072622185405900_bib17","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.cell.2015.01.016","article-title":"Intra-spike crosslinking overcomes antibody evasion by HIV-1","volume":"160","author":"Galimidi","year":"2015","journal-title":"Cell"},{"key":"2023072622185405900_bib18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0040435","article-title":"Plasma membrane is the site of productive HIV-1 particle assembly","volume":"4","author":"Jouvenet","year":"2006","journal-title":"PLoS Biol"},{"key":"2023072622185405900_bib19","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2380-z","article-title":"Human neutralizing antibodies elicited by SARS-CoV-2 infection","author":"Ju","year":"2020","journal-title":"Nature"},{"key":"2023072622185405900_bib20","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.35738","article-title":"Nuclear pore heterogeneity influences HIV-1 infection and the antiviral activity of MX2","volume":"7","author":"Kane","year":"2018","journal-title":"eLife"},{"key":"2023072622185405900_bib21","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.001439","article-title":"The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection","author":"Kellam","year":"2020","journal-title":"J. Gen. Virol"},{"key":"2023072622185405900_bib22","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1093\/infdis\/jiy098","article-title":"Human Coronavirus NL63 Molecular Epidemiology and Evolutionary Patterns in Rural Coastal Kenya","volume":"217","author":"Kiyuka","year":"2018","journal-title":"J. Infect. Dis"},{"key":"2023072622185405900_bib23","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a                        functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"key":"2023072622185405900_bib24","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.49875","article-title":"Rhabdo-immunodeficiency virus, a murine model of acute HIV-1 infection","volume":"8","author":"Liberatore","year":"2019","journal-title":"eLife"},{"key":"2023072622185405900_bib25","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1086\/500469","article-title":"Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome","volume":"193","author":"Liu","year":"2006","journal-title":"J.                        Infect. Dis"},{"key":"2023072622185405900_bib26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1440-1843.2006.00783.x","article-title":"Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance","volume":"11","author":"Mo","year":"2006","journal-title":"Respirology"},{"key":"2023072622185405900_bib27","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.1128\/JVI.74.8.3548-3554.2000","article-title":"Genetic evidence for an interaction between human immunodeficiency virus type 1 matrix and alpha-helix 2 of the gp41 cytoplasmic tail","volume":"74","author":"Murakami","year":"2000","journal-title":"J. Virol"},{"key":"2023072622185405900_bib28","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1080\/22221751.2020.1743767","article-title":"Establishment and validation of a                        pseudovirus neutralization assay for SARS-CoV-2","volume":"9","author":"Nie","year":"2020","journal-title":"Emerg. Microbes Infect"},{"key":"2023072622185405900_bib29","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.3201\/eid2510.190051","article-title":"Sensitive and Specific Detection of Low-Level Antibody Responses in Mild Middle East Respiratory Syndrome Coronavirus Infections","volume":"25","author":"Okba","year":"2019","journal-title":"Emerg. Infect. Dis"},{"key":"2023072622185405900_bib30","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.3201\/eid2210.160706","article-title":"Persistence of Antibodies against Middle East Respiratory Syndrome Coronavirus","volume":"22","author":"Payne","year":"2016","journal-title":"Emerg.                        Infect. Dis"},{"key":"2023072622185405900_bib31","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a                        human monoclonal SARS-CoV antibody","volume":"583","author":"Pinto","year":"2020","journal-title":"Nature"},{"key":"2023072622185405900_bib32","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin. Vaccine Immunol"},{"key":"2023072622185405900_bib44","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2456-9","article-title":"Convergent antibody responses to SARS-CoV-2 in convalescent individuals","author":"Robbiani","year":"2020","journal-title":"Nature"},{"key":"2023072622185405900_bib34","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc7520","article-title":"Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model","author":"Rogers","year":"2020","journal-title":"Science"},{"key":"2023072622185405900_bib35","doi-asserted-by":"crossref","unstructured":"Seydoux,E.,L.J.Homad,A.J.MacCamy,K.R.Parks,N.K.Hurlburt,M.F.Jennewein,N.R.Akins,A.B.Stuart,Y.-H.Wan,J.Feng, .2020. Characterization of neutralizing antibodies from a                    SARS-CoV-2 infected individual. bioRxiv. https:\/\/doi.org\/10.1101\/2020.05.12.091298 (Preprint posted May 12, 2020)","DOI":"10.1101\/2020.05.12.091298"},{"key":"2023072622185405900_bib36","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2381-y","article-title":"A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2","author":"Shi","year":"2020","journal-title":"Nature"},{"key":"2023072622185405900_bib37","doi-asserted-by":"crossref","unstructured":"Sterlin,D.,A.Mathian,M.Miyara,A.Mohr,F.Anna,L.Claer,P.Quentric,J.Fadlallah,P.Ghillani,C.Gunn, .2020. IgA dominates the early neutralizing antibody response to SARS-CoV-2. medRxiv.https:\/\/doi.org\/10.1101\/2020.06.10.20126532 (Preprint posted June 11, 2020)","DOI":"10.1101\/2020.06.10.20126532"},{"key":"2023072622185405900_bib38","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.virol.2006.11.027","article-title":"The intracellular sites of early replication and budding of SARS-coronavirus","volume":"361","author":"Stertz","year":"2007","journal-title":"Virology"},{"key":"2023072622185405900_bib39","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc7424","article-title":"Broad neutralization of SARS-related viruses by human monoclonal antibodies","author":"Wec","year":"2020","journal-title":"Science"},{"key":"2023072622185405900_bib40","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jviromet.2010.08.006","article-title":"Generation of VSV pseudotypes using recombinant \u0394G-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines","volume":"169","author":"Whitt","year":"2010","journal-title":"J. Virol. Methods"},{"key":"2023072622185405900_bib41","doi-asserted-by":"crossref","unstructured":"Wu,F.,A.Wang,M.Liu,Q.Wang,J.Chen,S.Xia,Y.Ling,Y.Zhang,J.Xun,L.Lu, .2020a. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications.medRxiv.https:\/\/doi.org\/10.1101\/2020.03.30.20047365 (Preprint posted April 20, 2020)","DOI":"10.1101\/2020.03.30.20047365"},{"key":"2023072622185405900_bib42","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1126\/science.abc2241","article-title":"A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2","volume":"368","author":"Wu","year":"2020","journal-title":"Science."},{"key":"2023072622185405900_bib43","doi-asserted-by":"crossref","unstructured":"Zost,S.J.,P.Gilchuk,J.B.Case,E.Binshtein,R.E.Chen,J.X.Reidy,A.Trivette,R.S.Nargi,R.E.Sutton,N.Suryadevara, .2020. Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals. bioRxiv.https:\/\/doi.org\/10.1101\/2020.05.22.111005 (Preprint posted May 22, 2020)","DOI":"10.1101\/2020.05.22.111005"}],"container-title":["Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/doi\/10.1084\/jem.20201181\/1789494\/jem_20201181.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/doi\/10.1084\/jem.20201181\/1789494\/jem_20201181.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T18:20:41Z","timestamp":1690395641000},"score":1,"resource":{"primary":{"URL":"https:\/\/rupress.org\/jem\/article\/217\/11\/e20201181\/151961\/Measuring-SARS-CoV-2-neutralizing-antibody"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,21]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11,2]]}},"URL":"https:\/\/doi.org\/10.1084\/jem.20201181","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.06.08.140871","asserted-by":"object"}]},"ISSN":["0022-1007","1540-9538"],"issn-type":[{"value":"0022-1007","type":"print"},{"value":"1540-9538","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,21]]},"article-number":"e20201181"}}